Literature DB >> 25420857

Differences in cardiac structure assessed by echocardiography between renal transplant recipients and chronic kidney disease patients.

E Dounousi1, M Mitsis1, K K Naka2, C Pappas1, L Lakkas2, C Harisis1, K Pappas2, V Koutlas1, I Tzalavra1, G Spanos1, L K Michalis2, K C Siamopoulos3.   

Abstract

BACKGROUND: Cardiovascular disease (CVD) is the leading cause of death in predialysis chronic kidney disease (CKD) and dialysis patients as well as in renal transplant recipients (RTRs). Left ventricular hypertrophy (LVH) starts early during the course of CKD and is a strong predictor of CVD in this population. Regression of LVH after a successful renal transplantation remains a debatable issue among investigators, whereas there is little data comparing echocardiographic measurements between patients with predialysis CKD and RTRs. AIM: The aim of this study was to compare echocardiographic measurements of LV structure and function between predialysis CKD patients and RTRs of similar renal function level. PATIENTS AND METHODS: We conducted a case control study with individual (1:2) matching from the Renal Transplant and the predialysis CKD Outpatient Clinic. For each of the 36 RTRs, two matched for gender, age and estimated glomerular filtration rate (eGFR) predialysis CKD outpatients (72 patients) were included. All patients underwent transthoracic echocardiography and LV mass, LV mass index [LVM and LVMI = LVM/BSA g/m(2)] and indices of systolic function were measured. In a subgroup of 12 RTRs we retrospectively assessed and compared the LVMI measurements at three different time points, during predialysis, dialysis and post transplant period.
RESULTS: The prevalence of LVH was 33% in RTRs and 52% in CKD patients (ns). RTRs had significantly lower LVM and LVMI levels compared with predialysis CKD patients (P = .006 and P = .008) while the other echocardiographic indices did not differ. In the subgroup of 12 RTRs, post-transplant LVMI levels (105 ± 25 g/m(2)) were significantly lower in comparison with predialysis (147 ± 57 g/m(2)) and dialysis LVMI levels (169 ± 72 g/m(2)) (P = .01, P = .01, respectively).
CONCLUSION: RTRs had significantly lower LVMI compared with predialysis CKD patients of similar age, renal function, hemoglobin and blood pressure level.

Entities:  

Mesh:

Year:  2014        PMID: 25420857     DOI: 10.1016/j.transproceed.2014.10.034

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  4 in total

1.  Longitudinal assessment of myocardial function in childhood chronic kidney disease, during dialysis, and following kidney transplantation.

Authors:  Rawan K Rumman; Ronand Ramroop; Rahul Chanchlani; Mikaeel Ghany; Diane Hebert; Elizabeth A Harvey; Rulan S Parekh; Luc Mertens; Michael Grattan
Journal:  Pediatr Nephrol       Date:  2017-03-08       Impact factor: 3.714

2.  Effect and correlation of patent vascular access flow on left ventricular hypertrophy in kidney transplant patients.

Authors:  Eakalak Lukkanalikitkul; Burabha Pussadhamma; Anucha Ahooja; Phuangpaka Ungprasert; Panorkwan Toparkngam; Supajit Nawapun; Wittawat Takong; Ubonrat Toimamueang; Sirirat Anutrakulchai
Journal:  Int J Cardiol Heart Vasc       Date:  2022-05-09

3.  Cardiovascular disease: Risk factors and applicability of a risk model in a Greek cohort of renal transplant recipients.

Authors:  Nikolaos-Andreas Anastasopoulos; Evangelia Dounousi; Evangelos Papachristou; Charalampos Pappas; Eleni Leontaridou; Eirini Savvidaki; Dimitrios Goumenos; Michael Mitsis
Journal:  World J Transplant       Date:  2017-02-24

4.  Cardiovascular Effects of Autologous Bone Marrow-Derived Mesenchymal Stromal Cell Therapy With Early Tacrolimus Withdrawal in Renal Transplant Recipients: An Analysis of the Randomized TRITON Study.

Authors:  Maria Chiara Meucci; Marlies E J Reinders; Koen E Groeneweg; Suzanne Bezstarosti; Nina Ajmone Marsan; Jeroen J Bax; Johan W De Fijter; Victoria Delgado
Journal:  J Am Heart Assoc       Date:  2021-12-16       Impact factor: 6.106

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.